Scholarlink

<p>Acute myeloid leukemia (AML) with mutated <i>NPM1</i> (Nucleophosmin 1) is a distinct entity in the 5th edition of the World Health Organization (WHO) Classification as well as a favourable risk category in the 2022 European LeukemiaNet (ELN) Recommendations for AML. The development of myriad techniques for detection of <i>NPM1</i> Measurable Residual Disease (MRD) has led to improved patient outcomes; however, there is no one winner. Each modality has its own nuances and caveats, and hence using a synoptic and integrated approach is recommended to avoid potential false negatives. Therapy guided by genomic MRD especially in decision for timing of transplant has been reported in literature, which has shown benefits of regular longitudinal monitoring of <i>NPM1</i>. This is a narrative review which discusses in detail the testing modalities for <i>NPM1</i> MRD in AML. Keywords like ‘NPM1”, “MRD”, “NGS”, were searched in Pubmed, Embase and Scopus and a total of 40 articles were included. Since this is not a systematic review or meta-analysis no inclusion or exclusion criteria were laid and no formal statistics was done. This article was constructed in pursuit of raising awareness for this unmet need, as well as to amalgamate all old and new knowledge in this space. The future is artificial intelligence and machine learning which may pave the way for risk scores.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NPM1 Measurable Residual Disease: A Narrative Review

  • 期刊论文

  • 发表日期：

    2025年1月27日

查看全文
  • Yadav Chitresh,
  • Nathany Shrinidhi,
  • Kumar Nikhil M.,
  • Swaminathan Anusha,
  • Panda Rastogi Neha,
  • Verma Kanika,
  • Saini Manish,
  • Verma Hari Stuti,
  • Danewa Arun,
  • Dua Vikas,
  • Bhargava Rahul

摘要

Acute myeloid leukemia (AML) with mutated NPM1 (Nucleophosmin 1) is a distinct entity in the 5th edition of the World Health Organization (WHO) Classification as well as a favourable risk category in the 2022 European LeukemiaNet (ELN) Recommendations for AML. The development of myriad techniques for detection of NPM1 Measurable Residual Disease (MRD) has led to improved patient outcomes; however, there is no one winner. Each modality has its own nuances and caveats, and hence using a synoptic and integrated approach is recommended to avoid potential false negatives. Therapy guided by genomic MRD especially in decision for timing of transplant has been reported in literature, which has shown benefits of regular longitudinal monitoring of NPM1. This is a narrative review which discusses in detail the testing modalities for NPM1 MRD in AML. Keywords like ‘NPM1”, “MRD”, “NGS”, were searched in Pubmed, Embase and Scopus and a total of 40 articles were included. Since this is not a systematic review or meta-analysis no inclusion or exclusion criteria were laid and no formal statistics was done. This article was constructed in pursuit of raising awareness for this unmet need, as well as to amalgamate all old and new knowledge in this space. The future is artificial intelligence and machine learning which may pave the way for risk scores.